DUBLIN--(BUSINESS WIRE)--The "Myelodysplastic Syndrome - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Myelodysplastic Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 14, 70, 56, 3, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 9, 8, 3, 2 and 2 molecules, respectively.
Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Myelodysplastic Syndrome - Overview
- Myelodysplastic Syndrome - Therapeutics Development
- Myelodysplastic Syndrome - Therapeutics Assessment
- Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
- Myelodysplastic Syndrome - Drug Profiles
- Myelodysplastic Syndrome - Dormant Projects
- Myelodysplastic Syndrome - Discontinued Products
- Myelodysplastic Syndrome - Product Development Milestones
For more information about this report visit https://www.researchandmarkets.com/research/kttjj9/myelodysplastic?w=4